OPNT News and Press, Opiant Pharmaceuticals Inc. From 11/24/22

NEW YORK, NY / ACCESSWIRE / November 24, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NA...

SANTA MONICA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for OPNT003...

MONSEY, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of Opiant Pharmaceuticals, Inc. (Nasdaq: OPNT) (“Opiant”) acted in the best interests of Opiant shareholders in approving the sale of Opiant to Indivi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roman Tiraspolsky / Shutterstock.com Party City (NYSE: PRTY ) is the latest company to announce layoffs as it prepares to cut 19% of its workforce . The holiday retailer announced that it will achieve...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock.com Opiant Pharmaceuticals (NASDAQ: OPNT ) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is offering to acquire shares of OPNT ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com Welcome back and get ready for the week with a breakdown of the biggest pre-market stock movers for Monday! The news moving stocks this morning includes an acquisition deal, ear...

Opiant Pharmaceuticals press release ( NASDAQ: OPNT ): Q3 GAAP EPS of -$1.93 misses by $0.42 . Revenue of $0.2M (-98.8% Y/Y) misses by $3.48M . As of September 30, 2022, Opiant had $35.4M in cash and cash equivalents. For further details see: Opi...

SANTA MONICA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and nine mo...

Indivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share in cash, payable on achievement of certain net revenue thresholds f...

Indivior To Acquire Opiant Pharmaceuticals PR Newswire Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well...